2020-01-30

Press releases

Update on 2cureX’s clinical trial in metastatic colorectal cancer: 75% of the scheduled patients have been treated in accordance with the IndiTreat test

2cureX AB (“2cureX”, NASDAQ: 2CUREX) is pleased to announce that 35 patients have been treated in accordance with the IndiTreat...

2020-01-06

Press releases regulatory

2cureX continues its IP expansion by securing a patent on its IndiTreat test in Australia

2cureX AB (“2cureX”, NASDAQ: 2CUREX) is pleased to announce the granting of an Australian patent (AU2015283320A) on its key product,...

2019-12-13

Press releases regulatory

2cureX presented progression in the IndiTreat® immuno-oncology assay development at the ESMO Immuno-Oncology Congress in Geneva 11-14 Dec. 2019.

2cureX AB (“2cureX”, NASDAQ: 2CUREX) announces that the company presented significant progression of the IndiTreat® test for individualizing immuno-oncological treatment...

2019-12-10

Press releases regulatory

2cureX launches IndiTreat.com as an important component of 2cureX’s preparation for the product launch of IndiTreat® in 2020

2cureX AB (“2cureX”, NASDAQ: 2CUREX) today announces that the company has launched www.IndiTreat.com. This website provides detailed information to colorectal...

2019-11-22

Press releases regulatory

2cureX publishes interim report for the third quarter of 2019

2cureX AB (“2cureX”) hereby publishes interim report for the third quarter of 2019. The interim report is available as an...

2019-11-06

Press releases regulatory

2cureX continues its efforts to ensure a strong IP protection for its IndiTreat test in the United States

2cureX AB (“2cureX”, NASDAQ: 2CUREX) is pleased to announce that a patent on the IndiTreat® test has been granted in...